Samsung Biologics clears minimum threshold in PolyPeptide tender offer
Shareholders tendered 87.88% of targeted shares at 44.31 Swiss francs each, well above the 66.7% minimum, in a 1.46 billion franc deal.
The wire
- 01Samsung Biologics said 29,014,418 shares were tendered through its Samsung Peptide SPC in the September 15 to October 12 offer, including all 18,375,000 shares held by largest shareholder Draupnir Holding.
- 02The purchase would hand a major CDMO peptide manufacturing capacity, relevant to anyone tracking supply for incretin and other peptide APIs.
- 03An additional tender period runs October 19 to 30, with closing targeted by end of November pending regulatory approvals in Europe, India, Australia and Brazil.
From the source
Read at asiae.co.krSamsung Biologics: "Polypeptide Group Tender Offer Meets Minimum Acceptance Condition"
Samsung Biologics recorded a tender acceptance rate of 87.88% in its tender offer for global peptide contract development and manufacturing organization (CDMO) Polypeptide Group, surpassing the 66.7% minimum required for the acquisition to proceed.
